

Specimen Collected: 03-Feb-26 12:12

11Q Aberrations by FISH Procedure	Received: 03-Feb-26 12:13	Report/Verified: 03-Feb-26 12:15
Procedure	Result	Units Reference Interval
11Q FISH Result	Loss and Gain ^{f1 i1}	
MLL Percent Gain	100	%
MLL Total Cell Count	100	
FLI1 Total Cell Count	100	
Scoring Method	Computer Assisted	
11Q FISH Reference Number	Q12	
11Q FISH Source	Lymphoma	

Result Footnote

f1: 11Q FISH Result

11Q aberration was DETECTED.

Controls were run and performed as expected.

This result has been reviewed and approved by Anton Rets, M.D.

Test Information

i1: 11Q FISH Result

INTERPRETIVE INFORMATION:

Fluorescence in situ hybridization (FISH) analysis was performed on sections from a paraffin embedded tissue block using differentially labeled fluorescent probes targeting the 11q23.3 (MLL), 11q24.3 (FLI1), and a chromosome 11 centromeric control region (Agilent Technologies). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin and eosin-stained section. Controls performed appropriately.

This test is designed to detect gain of the 11q23.3 (MLL) region and loss of the 11q24.3 (FLI1) region. An abnormal signal pattern seen in 25 percent or more of the evaluated tumor cells is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 95 percent of 11q aberrations in patients with High-Grade B-Cell Lymphoma with 11q aberrations, except for rare instances of complex genomic changes or copy-number neutral losses of heterozygosity. Assay range and limit of detection were generated using normal and known positive cases respectively.

Identification of 11q aberrations is useful in the diagnosis of High-Grade B-Cell Lymphoma with 11q aberrations (HGBL-11q).

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-034-900128**Report Request ID:** 20928670**Printed:** 03-Feb-26 17:45

Page 1 of 1